On July 23, 2026, the U.S. Food & Drug (FDA) Pharmacy Compounding Advisory Committee, also known as PCAC, voted in favor of expanding access to BPC-157. The committee voted 8 to 6, with one abstention, to recommend adding both BPC-157 free base and BPC-157 acetate to the FDA’s Section 503A Bulks List.
This landmark vote is an exciting step forward, but it is only one step in the process of expanding access to peptides. BPC-157 is not FDA approved, and the vote does not make it immediately available from 503A compounding pharmacies.
What Is BPC-157?
BPC-157, also called Body Protection Compound 157, is a peptide reported to contain 15 amino acids. It has gained a lot of attention for its potential role in digestive health and tissue recovery. However, most of the excitement surrounding BPC-157 comes from early research and online claims rather than large human clinical studies.
During a review, the FDA focused specifically on the possible use of BPC-157 for ulcerative colitis. The agency found that there was not enough evidence to determine whether it works for that condition. Human safety information is also still limited, especially for oral, nasal, injectable, and topical use.
What Is the FDA 503A Bulks List?
The FDA 503A Bulks List identifies certain bulk drug substances that traditional compounding pharmacies may use when preparing patient specific medications, even when those substances are not part of an FDA approved drug or recognized in an applicable official monograph.
Before a substance can be added, the FDA reviews available information about its safety, effectiveness, clinical need, and manufacturing quality. The Pharmacy Compounding Advisory Committee may then provide a recommendation, but the FDA makes the final decision.
Being recommended for the 503A Bulks List does not mean a substance is FDA approved. It simply means the substance may eventually be permitted for use in qualifying compounded medications under Section 503A. Therefore, the recent vote supporting BPC 157 is an important step, but it does not automatically make BPC 157 available for routine 503A compounding.
Why the PCAC Vote Matters
Section 503A allows licensed pharmacists and physicians to prepare customized medications for individual patients when certain requirements are met. When an ingredient is not part of an FDA approved drug and does not have an applicable official monograph, it may need to appear on the 503A Bulks List before it can be used for this type of compounding.
That is why this vote matters. It moves BPC-157 one step closer to a regulated pathway where it could potentially be prepared by qualified 503A pharmacies for patients with prescriptions.
The vote was also significant because the committee voted yes, even though FDA staff had recommended against adding BPC-157. Their concerns included limited human research, possible immune reactions, product quality, and unanswered questions about safety and effectiveness.
What the Vote Does Not Mean
The vote does not approve BPC-157 as a medication. It also does not prove that the peptide is safe or effective. Most importantly, it does not mean 503A pharmacies can immediately begin compounding it.
Even if BPC-157 is eventually added to the list, compounded products containing it would not become FDA approved drugs. Compounded medications do not go through the same FDA review for safety, effectiveness, and manufacturing quality as approved medications.
Safety and Evidence Still Matter
Interest in BPC-157 has grown much faster than the human research. FDA reviewers raised concerns about possible immune reactions, peptide related impurities, and the limited information available about its long term safety.
These concerns do not take away from the importance of the vote. They simply remind us that this is progress in a regulatory process, not confirmation that BPC-157 provides a proven medical benefit. Be cautious of any online seller or provider describing it as FDA approved, completely safe, or guaranteed to work.
What Happens Next?
The FDA will now consider the committee’s recommendation, its own scientific review, and the public record. Further agency action is required before BPC-157 can be formally added to the 503A Bulks List. There is currently no confirmed timeline for a final decision.
At River Oaks Galleria Medspa and Hair Institute, we are excited to see continued progress in peptide research and patient access. At the same time, we believe emerging treatments should always be discussed honestly and with proper medical guidance. Our Houston team will continue watching the FDA’s next steps and sharing meaningful updates as the status of BPC-157 develops.
To learn about Peptides, visit our Peptides Service Page.
Have questions about peptide therapy or the wellness options currently available at River Oaks Galleria Medspa? Contact our Houston, TX team to schedule a personalized consultation.
References
- U.S. Food and Drug Administration (FDA). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Available at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 and https://www.fda.gov/media/193343/download
- U.S. Food and Drug Administration (FDA). Bulk Drug Substances Used in Compounding. Available at: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
-
McDermott Will & Schulte. Client Alert: Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. Published July 27 2026. Available at: https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/
FAQs
No. PCAC recommended adding it to the 503A Bulks List, but this was not FDA drug approval.
Not because of this vote alone. Further FDA action is still required before its federal compounding status can change.
No. Human safety and effectiveness data remain limited, and more well designed clinical research is still needed.
